Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 2Gliosarcoma 2Glioblastoma 2Ependymoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Astrocytoma 2Precancerous Conditions 1Pinealoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Multiple Sclerosis 1Meningioma 1Medulloblastoma 1Liver Neoplasms 1Glioma 1Choroid Plexus Neoplasms 1

Interventions

gadobutrol 1gadobenic acid 1Registries 1Nivolumab 1Natalizumab 1Gadolinium DTPA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Sclerosis × Gadolinium DTPA × Clear all
NCT02967380 2017-03-27

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

University of Southern California

Phase NA Terminated
14 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Multiple Sclerosis, Oligodendroglioma, Pinealoma, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡